The latest report by IMARC Group, titled “Premenstrual Syndrome Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028“, The global premenstrual syndrome treatment market size reached US$ 1,346 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,683 Million by 2028, exhibiting a growth rate (CAGR) of 3.9% during 2023-2028.
Premenstrual syndrome (PMS) treatment options are aimed at alleviating the physical and emotional symptoms that many individuals experience in the days or weeks leading up to their menstrual period. PMS symptoms can vary in severity and type from person to person, so the choice of treatment may depend on the specific symptoms and their impact on an individual’s daily life. Some of the common approaches to managing PMS are lifestyle modifications, over-the-counter medications, prescription medications, and alternative therapies. Additionally, adopting a balanced diet rich in whole grains, fruits, vegetables, and lean proteins can help regulate blood sugar levels and reduce mood swings and cravings, with some regular physical activity to improve mood and reduce PMS symptoms with aerobic exercises, including walking, jogging, or swimming. Consequently, premenstrual syndrome (PMS) treatment also includes acupuncture, herbal supplements, and dietary supplements.
For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/premenstrual-syndrome-treatment-market/requestsample
Premenstrual Syndrome Treatment Market Trends and Drivers:
The premenstrual syndrome (PMS) treatment market is primarily driven by the growing awareness and diagnosis of PMS. As medical knowledge and awareness about women’s health issues have expanded, more individuals are recognizing their PMS symptoms and seeking medical advice, resulting in a larger patient pool, which is escalating the demand for PMS treatment options. Moreover, the growing acceptance of PMS as a legitimate medical condition, rather than a mere women’s issue, resulted in increased research and development (R&D) efforts to find effective treatments, representing another major growth-inducing factor. Also, healthcare providers are more inclined to discuss and diagnose PMS, leading to more individuals seeking treatment. Besides this, several advancements in the development of treatments for PMS, including lifestyle modifications, dietary changes, medications, and supplements, are accelerating the market growth. It allows healthcare providers to tailor solutions to the specific needs and preferences of patients. Along with this, pharmaceutical companies and healthcare providers are actively engaging in marketing and educating the public about PMS treatments, which raised awareness about available options, encouraging more individuals to consider treatment as a viable solution, further propelling market growth.
Report Segmentation:
The report has segmented the market into the following categories:
Breakup by Drug Type:
- Analgesics
- Antidepressants
- Oral Contraceptives and Ovarian Suppression Agents
- Others
Breakup by Type:
- Prescription
- Over-the-Counter
Breakup by Distribution Channel:
- Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Stores
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Competitive Landscape with Key Player:
- AbbVie Inc.
- BASF SE
- Bayer AG
- Dr. Reddy’s Laboratories Ltd
- Eli Lilly and Company
- GlaxoSmithKline Plc.
- H. Lundbeck A/S
- Pfizer Inc.
- SHIONOGI & Co. Ltd.
Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163
